Third Harmonic Bio, Inc. (THRD) Research

Third Harmonic Bio, Inc. is a clinical-stage biotechnology firm dedicated to creating therapeutic solutions for a range of allergic and inflammatory conditions. Their primary investigational compound is THB001, an orally administered small-molecule inhibitor targeting KIT. This compound is being advanced to address chronic urticaria—a skin ailment characterized by painful, itchy red welts (hives) stemming from mast cell overactivity—and is also being explored for its potential in respiratory and digestive tract disorders. Previously known as Project IGE, Inc., the company adopted its current name, Third Harmonic Bio, Inc., in June of 2019. Established in 2019, its corporate headquarters are situated in Cambridge, Massachusetts.

Market snapshot

Symbol
THRD
Price
$5.38
Day change
-0.09%
Market cap
$242.8M
P/E ratio
-8.35x
52-week range
3.18-16.02
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$16.15

Peer companies

  • Catabasis Pharmaceuticals, Inc. (CATB)
  • Celularity Inc. (CELU)
  • CARGO Therapeutics, Inc. Common Stock (CRGX)
  • Inozyme Pharma, Inc. (INZY)
  • Acelyrin, Inc. (SLRN)
  • Spectrum Pharmaceuticals, Inc. (SPPI)
  • Alaunos Therapeutics, Inc. (TCRT)
  • 2seventy bio, Inc. (TSVT)

Recent insider activity

  • Holles Natalie C. — J-Other (50000 shares) on 2025-08-11
  • Holles Natalie C. — J-Other (998854 shares) on 2025-08-11
  • Holles Natalie C. — J-Other (1218836 shares) on 2025-08-11
  • Gladstone Michael — J-Other (43584 shares) on 2025-08-11
  • Murphy Christopher M. — J-Other (47500 shares) on 2025-08-11

Open Third Harmonic Bio, Inc. (THRD) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.